Interpreting the TROP2 NMR Readout and What the Current Evidence Means Clinically

This segment transitions the conversation from biologic rationale to the practical interpretation of clinical and translational data supporting TROP2 NMR as a predictive biomarker for TROP2-directed ADCs. Dr. Wistuba explains that the value of NMR lies not only in what it measures (relative membrane versus cytoplasmic TROP2 signal) but also in how rigorously it is derived. Unlike conventional IHC scoring, which relies on semi-quantitative categorical grading, the NMR is calculated using computational pathology at the single-cell level. The algorithm evaluates at least 100 malignant cells per tumor sample, computes the ratio cell-by-cell, and then summarizes these measurements into an interpretable biomarker call.

A key point is that the NMR definition can feel counterintuitive: the ratio is calculated as membrane expression divided by total expression (membrane plus cytoplasmic). As a result, a lower NMR implies relatively greater cytoplasmic signal and is associated with improved therapeutic response, which is consistent with the biologic premise that cytoplasmic localization may reflect internalization and intracellular processing of the ADC. Dr. Wistuba clarifies the operational threshold used in current datasets: an NMR value of ≤0.56 is the cell-level cutoff, and a tumor is considered “NMR-positive” when ≥75% of malignant cells meet that criterion. The experts acknowledge the complexity of the definition but emphasize the core takeaway for communication and future implementation: lower NMR at the cell level, present across a high proportion of tumor cells, aligns with better outcomes.

Dr. Santos then addresses the real-world clinical question: could he use TROP2 NMR today to inform decision-making? He frames NMR as addressing a major unmet need. TROP2 ADCs have shown activity, but clinicians have lacked a reliable way to identify who is most likely to benefit. Based on currently available (largely retrospective) analyses, he describes the NMR findings as “provocative” and internally consistent, suggesting potential utility for risk stratification and tailoring follow-up intensity, even while acknowledging it is not yet prospectively validated or broadly available.

The segment closes with a forward-looking pathology perspective. Dr. Wistuba describes that biomarkers must be driven by clinical need rather than novelty; if TROP2 NMR proves predictive in prospective trials, pathology will have a responsibility to implement it correctly, whether as a companion diagnostic or future laboratory-developed test, within an increasingly digital pathology ecosystem.